Infective endocarditis is a rare infection associated with a high mortality. Patients are often admitted for prolonged periods of time to receive antibiotics. The Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis or the POET trial asked the question whether patients with left sided infective endocarditis can be switched to oral treatment after stabilization on intravenous antibiotics. In this episode, our expert Dr Henry Chambers discusses infective endocarditis and the recently published POET trial.
00:00 Introduction 01:23 Microbiology of infective endocarditis (IE) 04:11 Clinical signs and symptoms of IE 06:10 Diagnosis of IE 08:56 Imaging for IE 11:37 General treatment principles for IE 14:11 Surgical Indications for IE 15:20 Why is the POET trial important? 16:59 Trial design and patient characteristics 22:07 Antibiotic regimen in the trial 23:54 Primary outcome in the trial 25:38 Summary of the podcast 27:00 Conclusion
This podcast is part of the series, Curbside Consults, which complements the foundational information in Rotation Prep by taking a deep dive into key topics with expert clinicians and educators. As we explore the details of pathophysiology and critique the evidence behind clinical practice, these conversations are intended to give you a better understanding of the topic and greater confidence when treating your patients.
Dr. Henry "Chip" Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases. Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.
Amanda Fernandes is a 2018-2019 NEJM editorial fellow.